July 11, 2019

Frenova Renal Research’s scope has expanded to include a global footprint. Before this expansion, Frenova primarily served clinical researchers in North America.

Dedicated exclusively to renal research, Frenova supports sponsors and nephrologists conducting research specific to kidney disease and its adjacent conditions. Led by Kurt Mussina, MBA, president, Frenova provides access to a global network of clinical trial resources including approximately 350 research sites and 550 investigators. Before this expansion, Frenova offered access to approximately 250 research sites and 450 investigators.

A global footprint enables Frenova to broaden its reach and provide researchers centralized access to an exponentially larger pool of patients, sites, investigators, and data. Global scope and increased efficiency strengthen Frenova’s mission to advance the science of renal therapies that improve the quality of life for people living with kidney disease.

Frenova’s managed research site business and its F1RST Up® (Frenova Rapid Start Up) alliance of clinical research sites help simplify and expedite the startup of clinical trials investigating pharmaceuticals and medical devices designed to advance renal health worldwide. These resources, combined with Frenova’s bioinformatics and analytics capabilities, provide an unparalleled asset for biopharmaceutical and medical device companies seeking to advance the science of renal therapies.

Back to News